UPDATE: Credit Suisse Maintains Neutral On Incyte, Lowers Target To $86 After Co's Itacitinib Results Notes 'Given this result, we have removed all credit for itacitinib in our INCY mode (we only modeled S-N aGVHD) or approximately $4/share (at 65% PoS)'
Benzinga_Newsdesk